Complexdoc: together: “Enacademic” plus 49 more

Telegram pub (Rss)
История

История шевронов: Древний мир
Ещё в древние времена, когда только появилось социальное расслоение общества, возникли и знаки отличия. Это могли быть татуировки, вышивка на одежде, перья и бусы.

feedspot (Rss) VK Bot in Enacademic via enacademic / Raindrop.io -- Delivered by Feed43...

Posted: 05 Dec 2020 10:55 AM PST

feedspot (Rss)
VK Bot in Enacademic

via enacademic
/ Raindrop.io
-- Delivered by Feed43 service

Raindrop.io — All in One Bookmark Manager - web.archive.org
All in One Bookmark Manager. For your inspiration, read later, media and stuff.

Posted: 05 Dec 2020 10:29 AM PST

https://www.hottg.com/academic2ru/325310
https://www.hottg.com/academic2ru/325310

academic2.ru
academic2.ru (https://en.tgstat.com/channel/@academic2ru/269244)

academic2.ru (http://academic2.ru/) ² - altt.me (http://althottg.com/) academic2.ru (http://academic2.ru/) ² - Telegram https://ift.tt/3hgfHz5 Store.academic2.ru (http://store.academic2.ru/) is a web project safe and generally suitable for all ages. We found that English is the preferred language on Store Academic 2 pages.-- Delivered by Feed43 (http://feed43.com/) service

Enacademic

Posted: 05 Dec 2020 10:34 AM PST

https://tgchannels.org/channel/enacademic?size=30&lang=ru&first=1716885&start=0

Posted: 05 Dec 2020 10:52 AM PST

_{-- Delivered by Feed43 service}

feedspot (Rss) Telegram pub (Rss) Сукно Сукно́ —... Telegram pub...

Posted: 05 Dec 2020 10:53 AM PST

feedspot (Rss)
Telegram pub (Rss) Сукно Сукно́ —...

Telegram pub (Rss)

Сукно

Сукно́ — к...
https://t.me/enacademic/1716636

Telegram pub (Rss)

Сукно

Сукно́ — как правило шерстяная или
полушерстяная (иногда
хлопчатобумажная) ткань, на
поверхности которой волокна шерсти
настолько сбиты, переплетены между
собой, что совершенно закрывают
все

Enacademic

Posted: 05 Dec 2020 10:25 AM PST

English: The undoubted advantage of viscose fabric is its...
https://t.me/enacademic/1716668

The undoubted advantage of viscose fabric is its origin from natural resources, and therefore it does not cause allergies, absorbs moisture well, and the body in products made of viscose easily and freely "breathes". Recycling of viscose does not pose a risk to the environment.

Comparison with other fabrics

The vegetable fibers in the viscose fabric made it look like cotton . Which one is better? Viscose also absorbs moisture well, is pleasant to the touch and breathable. These fabrics are sometimes confused. They are really very similar. However, viscose is a less durable fabric, it wears out faster. If cotton is a very strong fabric even when wet, then viscose becomes vulnerable in water. But if you consider the low price, this disadvantage can be considered insignificant.

In the sun, viscose may have spots of a different, unusual color. So it can react to the action of ultraviolet light. Modern fabric manufacturers have learned to deal with these troubles. Viscose undergoes a special treatment that increases its strength. The use of staple fibers also has a positive effect on the quality of the fabric. Viscose refers to artificial fibers, sometimes it is compared to polyester. But these are completely different fabrics. Natural raw materials of viscose equated the material, by some indicators, to natural fabrics. If the choice is polyester or viscose, the winner will be viscose . It is hygroscopic and breathable, which is not the case with polyester.

via forma-odezhda.ru (http://forma-odezhda.ru/) https://ift.tt/2w6FNml

Manage

Unsubscribe from these notifications or sign in to manage your Email service.

IFTTT

Manage on IFTTT:
https://ifttt.com/myrecipes/personal/114575676

This entry was originally posted at

Telegram
Enacademic

https://tgchannels.org/channel/enacademic?size=30&lang=ru&first=1716883&start=0

Posted: 05 Dec 2020 10:52 AM PST

_{-- Delivered by Feed43 service}

Posted: 05 Dec 2020 10:38 AM PST

Telegram pub (Rss)
История

История шевронов: Древний мир
Ещё в древние времена, когда только появилось социальное расслоение общества, возникли и знаки отличия. Это могли быть татуировки, вышивка на одежде, перья и бусы.

... httpst.meformaodezhdaru303313

Posted: 05 Dec 2020 10:42 AM PST

... https://ift.tt/33PHXo6 https://ift.tt/37Bba7a

Соки, Воды

Posted: 05 Dec 2020 10:42 AM PST

Соки, Воды https://ift.tt/33P1W6d

Enacademic

Posted: 05 Dec 2020 10:34 AM PST

Yandex.Translate in Enacademic

Posted: 05 Dec 2020 10:34 AM PST

enacademic.com Cutty Sark â€“ Wikipedie Robert Burns dal toto jmÃ©no ÄarodÄ›jnici...

Posted: 05 Dec 2020 10:42 AM PST

enacademic.com Cutty Sark â€" Wikipedie Robert Burns dal toto jmÃ©no ÄarodÄ›jnici... https://ift.tt/3mMVc0e

https://tgchannels.org/channel/enacademic?size=30&lang=ru&first=1716894&start=0

Posted: 05 Dec 2020 10:52 AM PST

_{-- Delivered by Feed43 service}

Новости пятой колонны: Это другое

Posted: 05 Dec 2020 11:03 AM PST

Написал xaerostar на mp.d3.ru / комментировать

Вашингтонский обком даёт указания

Posted: 05 Dec 2020 11:03 AM PST

Посольство США в Берлине призвало ФРГ и Европейский союз наложить мораторий на строительство газопровода "Северный поток — 2".

Как заявила газете Handelsblatt исполняющая обязанности посла Штатов в Германии Робин Куинвилл, такое решение стало бы четким сигналом, что ЕС больше не будет мириться с "постоянным злонамеренным поведением России".

По словам дипломата, "Северный поток — 2" — это "не просто экономический проект", а "политический инструмент", направленный на то, "чтобы обойти Украину и разделить Европу".

Написал experov на experov.d3.ru / комментировать

full digest (Rss) @formaodezhdaru posted a photo Don't have Telegram yet?...

Posted: 05 Dec 2020 10:27 AM PST

full digest (Rss)
@formaodezhdaru posted a photo

Don't have Telegram yet? Try it now!

Context

Embed

View In Channel

Copy

Posted: 05 Dec 2020 10:33 AM PST

https://altt.me/tg.php?https://t.me/enacademiccom/104102

-- Delivered by Feed43 (http://feed43.com/) service

Enacademic

Posted: 05 Dec 2020 10:34 AM PST

Killy Купить -

Posted: 05 Dec 2020 10:30 AM PST

Французская компания Killy относится к числу крупнейших производителей одежды для горнолыжного спорта. 40-летняя история успеха этого легендарного бренда неразрывно связана с именем ее создателя,

Yandex.Translate in Enacademic

Posted: 05 Dec 2020 10:42 AM PST

https://ift.tt/2JRiumW

Поўны цёзка героя Беларусі падпісаў ліст праўладных спартсменаў

Posted: 05 Dec 2020 10:34 AM PST

6 пьянь — и; ж. собир. Обычно бранно. Об алкоголиках,...

Posted: 05 Dec 2020 10:42 AM PST

* 6 пьянь — и; ж. собир. Обычно бранно. Об алкоголиках,... https://ift.tt/2L5JTlD

https://tgchannels.org/channel/enacademic?size=30&lang=ru&first=1716879&start=0

Posted: 05 Dec 2020 10:52 AM PST

_{-- Delivered by Feed43 service}

culpa levísima

Posted: 05 Dec 2020 10:34 AM PST

Структура

Posted: 05 Dec 2020 10:35 AM PST

Армия в той или иной степени касается каждого гражданина, поэтому волей-неволей люди осведомлены о ней. Но ведь армия это слишком обобщенное и абстрактное понятие...

via forma full 5 https://ift.tt/2VK5i6V

Manage

Unsubscribe from these notifications or sign in to manage your Email service.

IFTTT

Manage on IFTTT:
https://ifttt.com/myrecipes/personal/114580525

This posting includes an audio/video/photo media file: Download Now

Enacademic

Posted: 05 Dec 2020 10:34 AM PST

https://www.hottg.com/enacademiccom/103937 https://www.hottg.com/enacademiccom/103937 enacademic.com Murder...

Posted: 05 Dec 2020 10:53 AM PST

https://www.hottg.com/enacademiccom/103937
https://www.hottg.com/enacademiccom/103937

enacademic.com
Murder of Paul Broussard - Academic Dictionaries and ... (https://enacademic.com/dic.nsf/enwiki/11778312)

Paul Broussard (1964–1991), a 27 year-old Houston-area banker and Texas A&M alumnus, was beaten and stabbed to death in a gay-bashing outside a Houston nightclub on July 4, 1991 by ten teenaged boys.The youths had driven from the northern Houston suburb of The Woodlands to the heavily gay area of Montrose solely to "beat up some queers," in the words of one of the convicted teens.-- Delivered by Feed43 (http://feed43.com/) service

httpst.meformaodezhdaru303309 Forma-odezhda.ru httpst.meformaodezhdaru303308forma-odezhda.ru Панама...

Posted: 05 Dec 2020 10:42 AM PST

https://ift.tt/3qy0M92 Forma-odezhda.ru https://ift.tt/3lJ5VXZ Панама... https://ift.tt/33MwZjg

Poseida Therapeutics Provides Update On Phase 1 Trial Of P-BCMA-101 At The 2020 American Society Of Hematology Annual Meeting

Posted: 05 Dec 2020 10:45 AM PST

SAN DIEGO, Dec. 5, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (PSTX) , a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today reported results of an ongoing Phase 1 clinical trial of P-BCMA-101, an autologous chimeric antigen receptor T-cell (CAR-T) product candidate in relapsed/refractory multiple myeloma, during an oral presentation at the 2020 American Society of Hematology (ASH) Annual Meeting. The results show that patients treated with equivalent doses of product manufactured with a modified nanoplasmid process in the expanded Phase 1 trial achieved deeper responses while maintaining a similar safety profile compared to product manufactured with the Company's legacy plasmid.

"Based on the dual benefits of improved efficacy and consistent safety demonstrated with the new nanoplasmid, we are moving forward with this optimized manufacturing method in all of our CAR-T programs," said Eric Ostertag, M.D., Ph.D., chief executive officer of Poseida Therapeutics. "Furthermore, using our first-generation plasmid, we saw higher response rates as we escalated to higher dose cohorts not yet reached with the nanoplasmid product. We are currently moving into higher dosing cohorts with the nanoplasmid manufactured P-BCMA-101 product candidate and are optimistic further increases in effectiveness and durability are possible at these higher doses. We expect to finalize our Phase 2 dose in the first quarter of 2021."

The Phase 1 dose escalation trial initially included five cohorts with a product candidate created using a standard plasmid process. The trial was expanded in 2020 to include cohorts utilizing a new nanoplasmid manufacturing process. The nanoplasmid technology allows for a reduction in the plasmid backbone size, enhancing the transposition efficiency during manufacturing and improving the final CAR-T product performance. The expansion part of the trial is also evaluating several novel dosing strategies with 19 patients treated as of the data cutoff with a variety of dosing regimens, including single administration, cyclic dosing, combination with rituximab, and combination with lenalidomide.

Using the new manufacturing process, a dose of 0.75 x 10 6 cells/kg was administered to eight patients in the initial P-BCMA-101 nanoplasmid expansion cohorts. Patients treated in this cohort and evaluable by International Myeloma Working Group (IMWG) criteria (n=6) showed a higher response rate, with an ORR of 67 percent as compared to an ORR of 50 percent for the same dosing cohort using the standard P-BCMA-101 plasmid (n=2). Additionally, as of the cutoff date, three patients achieved deeper responses of either very good partial response (VGPR) or complete response (CR) in the nanoplasmid expansion cohort as compared to no patients reaching a VGPR or CR in the standard plasmid group at the Cohort 1 dose. As of the data cutoff date, two of the three nanoplasmid patients who reached VGPR or CR remained in durable responses at approximately 6 months.

"We observed an excellent efficacy and safety profile with a single dose escalation. There were very low rates of CRS with no ICU admissions for CRS, resulting in a safety profile suggesting this therapy could be delivered to a greater number of patients in a community hospital or outpatient setting," said Caitlin Costello, MD, Associate Clinical Professor of Medicine and member of the Division of Blood and Marrow Transplantation at University of California, San Diego. Dr. Costello is the principal investigator in the study, who presented the data during the ASH meeting.

At the 0.75 x 10 6 cells/kg dose, cytokine release syndrome (CRS) was seen in just one, or 12.5%, of evaluable Phase 1 nanoplasmid patients (n=8) and neurotoxicity was not seen in any patients, demonstrating the preservation of the product safety profile within the expansion cohort. The Company believes this highly favorable safety profile can be attributed to the gradual expansion of stem cell memory T (Tscm) cells when compared with published data from competitor products comprised of a higher percentage of T effector and other differentiated T cells (2-3 weeks to peak versus 3-7 days for most CAR-T cells). There have been no patient deaths, dose limiting toxicities or unexpected/off-target toxicities related to P-BCMA-101. The most common adverse events were cytopenias and infections generally attributable to lymphodepleting chemotherapy regimens. Based on the safety results, the protocol was amended to allow fully outpatient CAR-T cell administration.

The median patient age was 60, with a median time since diagnosis of approximately five years. Patients were heavily pre-treated, with a median of eight prior lines of therapy (2-18). All patients had received a protease inhibitor or at least one IMid, and nearly all patients had been previously treated with a CD38 monoclonal antibody. Sixty percent of the patients were refractory to all three drug classes, and four patients had previously received an anti-BCMA targeted therapy.

This open label, multicenter Phase 1 study is designed to assess the safety of P-BCMA-101 in subjects with relapsed and/or refractory multiple myeloma and includes multiple exploratory cohorts to evaluate the administration of P-BCMA-101 CAR-T within the framework of moving from the standard plasmid CAR-T product to the nanoplasmid product. The primary objective of this study is to determine the safety and maximum-tolerated dose of P-BCMA-101. Secondary objectives include anti-myeloma effect of P-BCMA-101. Additional information about the Phase 1 clinical study of P-BCMA-101 is available at www.clinicaltrials.gov using identifier: NCT03288493.

About P-BCMA-101P-BCMA-101 is an autologous CAR-T therapy which is currently being evaluated in an expanded Phase 1 clinical trial for the treatment of patients with relapsed/refractory multiple myeloma to inform the potentially registrational Phase 2 clinical trial. P-BCMA-101 targets cells that express B cell maturation antigen, or BCMA, which is expressed on essentially all multiple myeloma cells. P-BCMA-101 is engineered with Poseida's non-viral piggyBac ® DNA Modification System, resulting in a high percentage of T stem cell memory cells. P-BCMA-101 is composed primarily of Tscm, a very young subset of T cells that are long-lived, self-renewing and multipotent, with the capacity to reconstitute the entire spectrum of T cell subsets, including T effector cells. They also survive for decades, and potentially for entire lifespans, with non-CAR-Tscm cells normally providing lifelong T cell immunity against some infectious agents. P-BCMA-101 received regenerative medicine advanced therapy (RMAT) status and orphan drug designation from the FDA. Preliminary results from the Company's ongoing Phase 1 clinical trial suggest that P-BCMA-101 may have improved response rates with a favorable safety profile compared to published results from clinical trials of other CAR-T therapies at similar doses. The Phase 1 study is funded in part by the California Institute for Regenerative Medicine.

About Poseida Therapeutics, Inc.Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.

Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the clinical data presented, the potential benefits of Poseida's technology platforms and product candidates and Poseida's plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future clinical results could be inconsistent with results observed to date and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View original content to download multimedia: http://www.prnewswire.com/news-releases/poseida-therapeutics-provides-update-on-phase-1-trial-of-p-bcma-101-at-the-2020-american-society-of-hematology-annual-meeting-301186752.html

SOURCE Poseida Therapeutics, Inc.

Светский обозреватель Светлана Конеген, писатель Виктор Ерофеев и телеведущий Андрей Малахов, 1997 год, Россия

Posted: 05 Dec 2020 11:09 AM PST

В конце 90–х журналист и светский обозреватель Светлана Конеген носила красные волосы и очки с синими стеклами на кончике носа; телеведущий Андрей Малахов был ее вечным спутником, а писатель Виктор Ерофеев с тех пор почти не изменился.

Написал elicaster на historyporn.d3.ru / комментировать

feedspot (Rss) Telegram pub (Rss) Сукно Сукно́ —... Telegram pub...

Posted: 05 Dec 2020 10:53 AM PST

feedspot (Rss)
Telegram pub (Rss) Сукно Сукно́ —...

Telegram pub (Rss)

Сукно

Сукно́ — к...
https://t.me/enacademic/1716636

Telegram pub (Rss)

Сукно

Сукно́ — как правило шерстяная или
полушерстяная (иногда
хлопчатобумажная) ткань, на
поверхности которой волокна шерсти
настолько сбиты, переплетены между
собой, что совершенно закрывают
все

Enacademic

Posted: 05 Dec 2020 10:38 AM PST

Неизвестная команда. Используйте /help, чтобы получить список доступных команд.

academic2.ru (Rss) польза

Posted: 05 Dec 2020 10:42 AM PST

academic2.ru (Rss) польза https://ift.tt/3qwq33h

Posted: 05 Dec 2020 10:38 AM PST

العربية: Telegram pub (Rss)
التاريخ

تاريخ شيفرون: العالم القديم
حتى في العصور القديمة ، عندما ظهر فقط التقسيم الاجتماعي للمجتمع ، كانت هناك أيضا شارة. يمكن أن يكون الوشم, التطريز على الملابس ، والريش والخرز.

Вискоза https://analogindex.livejournal.com/2097465.html Вискоза ( Viscose )...

Posted: 05 Dec 2020 10:36 AM PST

Вискоза
https://analogindex.livejournal.com/2097465.html

Вискоза ( Viscose ) –...
https://t.me/enacademic/1716658

Вискоза
https://analogindex.livejournal.com/2097465.html

Вискоза ( Viscose ) – первое искусственное полотно, которое было получено человеком. Вискоза (в переводе с латинского «viscosus» означает «вязкий») – это искусственное волокно, которое получается путем переработки целлюлозы. Представляет из себя мягкое, приятное на ощупь волокно, обладающее высокой интенсивностью цвета и мягким блеском.

История ткани

В 1664 году натуралист из Англии Роберт Хук решил проверить гипотезу о том, что искусственные нити можно прясть от химической субстанции. Эти эксперименты продолжались длительное время, но так и не увенчались успехом. Процесс регенерации целлюлозы из раствора при добавлении кислоты в ее концентрированный медноаммиачный (то есть содержащий сульфат меди и гидроксид аммония) водный раствор был описан англичанином Дж. Мерсером около 1844. В 1855 году Джордж Аудемарс путем медленного понижения иглы в клейкую мякоть древесной коры и резины смог получить нить. Этот процесс требовал определенных навыков и точности, и с финансовой точки зрения был довольно дорог.

Через несколько десятков лет французский ученый Гильер де Шардоне уже запатентовал свой технологический процесс производства вискозного волокна. Данное волокно имело огромный недостаток – это легкое воспламенение, и поэтому от данного полотна отказались все швейные предприятия. Но первое промышленное применение этого метода, положившее начало промышленности медно- аммиачного волокна, приписывается Е.Швейцеру (1857), а дальнейшее его развитие — заслуга М.Крамера и И.Шлоссбергера (1858). В 1891 году английский химик Чарльз Фредерик Кросс и его сотрудники Эдвард Джон Беван и Клейтон Бидл разработали процесс ксантогенирования. И только в 1892 Кросс, Бевин и Бидл в Англии изобрели процесс получения вискозного волокна: вязкий (откуда название вискоза ) водный раствор целлюлозы получался после обработки целлюлозы сначала крепким раствором едкого натра, что давало «натронную целлюлозу», а затем — дисульфидом углерода (CS 2 ), в результате чего получался растворимый ксантогенат целлюлозы. При выдавливании струйки этого «прядильного» раствора через фильеру с малым круглым отверстием в кислотную ванну целлюлоза регенерировалась в форме вискозного волокна. При выдавливании раствора в такую же ванну через фильеру с узкой щелью получалась пленка, названная целлофаном. Ж.Бранденбергер, занимавшийся во Франции этой технологией с 1908 по 1912, первым запатентовал непрерывный процесс изготовления целлофана.

Позднее вискоза проходила перфорированные фильеры, затем осуществление коагуляции раствора в серной кислоте, натрии и сульфате цинка. Полученные волокна вытягивали, промывали, скручивали, замасливали и превращали в длинные тонкие нити.

30 сентября 1902 года был запатентован искусственный шёлк ( вискоза ).

В начале 20 века эта ткань получила особое распространение.

Тогда полиэстер еще не мог составить ей конкуренцию в виду того, что его волокна научились производить лишь в середине 20 века. Да и долгое время полиэстер использовался только для создания упаковки и других бытовых изделий.

В СССР первые производства вискозных волокон начали появляться в 1927 году, в городах Мытищи, Ленинград, Могилёв и Клин. Проектирование предприятий велось проектным институтом ГИПРОИВ.

В нашей стране словом «синтетика» привыкли называть именно вискозную материю, потому что из всех искусственных полотен ее использовали в пошиве одежды чаще всего.

Результатом развития новых технологий обработки вискозных волокон стали материалы тенсел и микро модал , обладающие новыми уникальными свойствами.

Виско́зное волокно́

Виско́зное волокно́ (от латинск

This posting includes an audio/video/photo media file: Download Now

academic_post in academic2group

Posted: 05 Dec 2020 10:34 AM PST

feedspot (Rss) kruke machen - Berlinerische Deutsch Wörterbuch Schlagen Sie auch in anderen...

Posted: 05 Dec 2020 10:53 AM PST

feedspot (Rss)
kruke machen - Berlinerische Deutsch Wörterbuch

Schlagen Sie auch in anderen Wörterbüchern nach: Krug, der —
Der Krug, des es, plur. die Krüge, Diminut. das Krügelchen,
Oberd. Krüglein, zusammen ...

Enacademic

Posted: 05 Dec 2020 10:34 AM PST

Posted: 05 Dec 2020 10:38 AM PST

Неизвестная команда. Используйте /help, чтобы получить список доступных команд.

clippers

Posted: 05 Dec 2020 10:34 AM PST

https://www.hottg.com/academic2ru/325305 https://www.hottg.com/academic2ru/325305 academic2.ru...

Posted: 05 Dec 2020 10:32 AM PST